Novel therapies targeting the endothelium in sickle cell disease

Hemoglobin

Volumn 35, Issue 5-6, 2011, Pages 530-546

  Hoppe, Carolyn C ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Endothelial dysfunction; Review; Sickle cell disease; Therapies; Vasculopathy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARGININE BUTYRATE; ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CLOTRIMAZOLE; DOCOSAHEXAENOIC ACID; EPTIFIBATIDE; GLUTAMINE; GMI 1070; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; LEVACECARNINE; MAGNESIUM SULFATE; PANOBINOSTAT; PRASUGREL; PROPRANOLOL; PYROGLUTAMATE MAGNESIUM; SALAZOSULFAPYRIDINE; SENICAPOC; SILDENAFIL; SIMVASTATIN; THIOCTIC ACID; TINZAPARIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

CYTOTOXICITY; DRUG TARGETING; ENDOTHELIUM INJURY; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; GENE EXPRESSION; HEMATOLOGICAL PARAMETERS; HUMAN; IN VITRO STUDY; INFLAMMATION; LEUKOCYTOSIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN POLYMERIZATION; RECEPTOR UPREGULATION; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 81055147569     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.606482     Document Type: Review

References (87)

1. Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J Lab Clin Med. 1997;129(3):288-293. (Pubitemid 27169430)
2. Solovey A, Lin Y, Browne P, Choong S,Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337(22):1584-1590. (Pubitemid 27509761)
3. Phelan MW, Faller DV. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol. 1996;167(3):469-476. (Pubitemid 26168223)
4. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1 α. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest. 1992;90(6):2333-2339. (Pubitemid 23010050)
5. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106(3):337-338. (Pubitemid 30655633)
6. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992; 84(7):611-615.
7. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92(7):2551-2555. (Pubitemid 28453000)
8. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995;96(2):1145-1151.
9. Shiu YT, Udden MM, McIntire LV. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood. 2000;95(10):3232-3241. (Pubitemid 30321179)
10. Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med. 2001;20(1):47-72. (Pubitemid 32168002)
11. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1): 270-280. (Pubitemid 38879868)
12. Enenstein J, Milbauer L, Domingo E, et al. Proinflammatory phenotype with imbalance of KLF2 and RelA: risk of childhood stroke with sickle cell anemia. Am J Hematol. 2010;85(1):18-23.
13. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91(11):4216-4223. (Pubitemid 28261985)
14. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101(9):1899-1904. (Pubitemid 28226109)
15. de Jong K, Emerson RK, Butler J, Bastacky J, Mohandas N, Kuypers FA. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood. 2001;98(5): 1577-1584.
16. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114(8):1136-1145. (Pubitemid 39578703)
17. Banerjee T, Kuypers FA. Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells. Br J Haematol. 2004;124(3):391-402. (Pubitemid 38167992)
18. Nath KA,Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158(3):893-903. (Pubitemid 32221782)
19. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389. (Pubitemid 36019423)
20. Aslan M, Freeman BA. Oxidases and oxygenases in regulation of vascular nitric oxide signaling and inflammatory responses. Immunol Res. 2002;26(1):107-118. (Pubitemid 35177489)
21. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, Morris SM Jr. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med. 2004;170(2):148-153. (Pubitemid 38925160)
22. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004;36(6):707-717. (Pubitemid 38264415)
23. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, PallerMS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 2000;96(1):314-320. (Pubitemid 30456487)
24. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res. 2001;2(5):280-285. (Pubitemid 34189652)
25. Brugnara C. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Curr Opin Hematol. 1995;2(2):132-138.
26. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA- 17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003;101(6):2412-2418. (Pubitemid 36302090)
27. Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111(8):3991-3997.
28. De Franceschi L, Beuzard Y, Jouault H, Brugnara C. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietarymagnesium intake in transgenic SAD mouse. Blood. 1996;88(7):2738-2744. (Pubitemid 26327528)
29. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1997;100(7):1847-1852. (Pubitemid 27431344)
30. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000;108(2):284-289. (Pubitemid 30143642)
31. Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol. 2008;140(1):80-85. (Pubitemid 350233253)
32. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl J Med. 1995;332(20):1317-1322.
33. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656. (Pubitemid 14054015)
34. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322(15): 1037-1045. (Pubitemid 20146662)
35. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89(3):1078-1088. (Pubitemid 27121303)
36. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27(4):204-210.
37. DeSimone J, Heller P, Schimenti JC, Duncan CH. Fetal hemoglobin production in adult baboons by 5-azacytidine or by phenylhydrazine-induced hemolysis is associated with hypomethylation of globin gene DNA. Prog Clin Biol Res. 1983;134:489-500.
38. DeSimone J, Biel M, Heller P. Maintenance of fetal hemoglobin (Hb F) elevations in the baboon by prolonged erythropoietic stress. Blood. 1982;60(2):519-523. (Pubitemid 12048702)
39. Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M. 5-Azacytidine increases Hb F production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood. 1985;66(3):527-532. (Pubitemid 15230754)
40. Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62(2):370-380. (Pubitemid 13036087)
41. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99(11):3905-3908. (Pubitemid 35332025)
42. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96(7):2379-2384.
43. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102(12):3865-3870. (Pubitemid 37486964)
44. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790-1797. (Pubitemid 29128478)
45. McMahon L,Tamary H, Askin M, et al. A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol. 2010;151(5):516-524.
46. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115(12):2483-2490.
47. Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 2004;104(10):3378-3385. (Pubitemid 39507162)
48. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98(6):1955-1962.
49. Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010;116(10):1779-1786.
50. Wun T, De Castro L, Styles L, et al. Effects of GMI-1070, a pan-selectin inhibitor, on leukocyte adhesion in sickle cell disease: results from a phase 1/2 study. Blood. 2010;116(21):262a.
51. Matsui NM,Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 2002;100(10):3790-3796. (Pubitemid 35303953)
52. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2):392-396. (Pubitemid 47250243)
53. Finnegan EM, Barabino GA, Liu XD, Chang HY, Jonczyk A, Kaul DK. Small-molecule cyclic αVβ3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion. AmJ Physiol Heart Circ Physiol. 2007;293(2):H1038-H1045. (Pubitemid 47254203)
54. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000;95(2):368-374. (Pubitemid 30041643)
55. Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood. 2007;110(7):2708-2717. (Pubitemid 47523194)
56. Lee SP, Ataga KI, Zayed M, et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol. 2007;139(4):612-620. (Pubitemid 350043807)
57. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96(7):2451-2459.
58. Kollander R, Solovey A, Milbauer LC, Abdulla F, Kelm RJ Jr, Hebbel RP. Nuclear factor-? B (NF?B) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Transl Res. 2010;155(4):170-177.
59. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287(1):H293-H301. (Pubitemid 38802365)
60. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001;97(7):1937-1941. (Pubitemid 32239070)
61. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840-846. (Pubitemid 38970583)
62. Kato GJ, Hunter C, Hunter L, et al. Atorvastatin therapy restores nitric oxide-dependent vascular responsiveness in patients with sickle cell disease. Blood. 2004;104(11):72a.
63. Hoppe CC, Stewart KR, Higa A, et al. The effect of simvastatin on markers of vascular dysfunction in patients with sickle cell disease. Blood. 2009;114:260a.
64. Niihara Y, Zerez CR, Akiyama DS, Tanaka KR. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998;58(2):117-121. (Pubitemid 28268087)
65. Niihara Y, Matsui NM, Shen YM, et al. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 2005;5:4.
66. Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 2004;26(10):619-625. (Pubitemid 39350393)
67. Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemost. 2001;85(6):966-974. 546 C. (Pubitemid 32573744)
68. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003;289(9):1136-1142. (Pubitemid 37430328)
69. Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85(10):800-802.
70. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41(12):1771-1780. (Pubitemid 44839141)
71. Kaul DK, Zhang X, Dasgupta T, Fabry ME. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295(1):H39-H47.
72. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99(4):1103-1108. (Pubitemid 34547059)
73. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168(1):63-69. (Pubitemid 37046634)
74. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000;22(6):515-520.
75. Little JA, Hauser KP, Martyr SE, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol. 2009;82(4):315-321.
76. Styles LA. Nitric oxide effects in sickle cell disease. Blood. 2008;112:48a.
77. Gordeuk VR. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):433-434.
78. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130(3):445-453. (Pubitemid 43899595)
79. Machado RF, Barst RJ, Yovetich NA, et al. Safety and efficacy of sildenafil therapy for Dopplerdefined pulmonary hypertension in patients with sickle cell disease: preliminary results of theWalk- PHaSST clinical trial. Blood. 2009;114:571a.
80. Mack AK, McGowan VR, Tremonti CK, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Haematol. 2008;142(6):971-978.
81. Yuditskaya S,Tumblin A, Hoehn GT, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood. 2009;113(5): 1122-1128.
82. Hsu L, Ataga KI, Gordeuk VR, et al. Tetrahydrobiopterin (6R-BH4): novel therapy for endothelial dysfunction in sickle cell disease. Blood. 2008;112:5a.
83. Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxiainduced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5):1924-1933. (Pubitemid 351632394)
84. Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber H W. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Resp Crit Care Med. 1997;156(1):280-285. (Pubitemid 27293202)
85. Werdehoff SG, Moore RB, Hoff CJ, Fillingim E, Hackman AM. Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy. Am J Hematol. 1998;58(3):195-199. (Pubitemid 28303547)
86. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149(3):426-435.
87. Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol. 2009;147(5):737-743.